47 Healthcare Deals, $5.6 Billion, One Week: Every Type of Capital Is Chasing Biotech

In a single week, 47 healthcare and biotech deals moved $5.6 billion across venture capital, M&A, private credit, and fund formation. That number is not driven by one mega-deal skewing the average. It is the result of capital arriving from every direction at once — Novartis writing a $2 billion check for a PI3K inhibitor program, Blackstone structuring $1.3 billion in credit financing for a pharma combination, and a biotech seed round quietly closing at $69 million.

When VC, strategic acquirers, credit funds, and continuation vehicles all converge on the same sector in the same week, something structural is happening. Here is what the data shows.

M&A and Credit Are Doing the Heavy Lifting

Venture capital gets the headlines, but this week the biggest healthcare capital flows came from M&A and private credit. Novartis's $2 billion acquisition of Synnovation Therapeutics' PI3Kα inhibitor program was the week's largest deal — a bet on next-generation cancer targeting that signals big pharma's appetite for clinical-stage assets has not faded.

On the credit side, Blackstone Credit & Insurance led a $1.3 billion financing package to support the combination of Paratek Pharmaceuticals and Radius Health. This is exactly the kind of deal that would have been bank-financed three years ago. Private credit is filling the gap across sectors, but in healthcare — where the cash flows are predictable and the assets are defensible — the fit is particularly clean.

QHP Capital's $1.1 billion continuation fund for Azurity Pharmaceuticals rounds out the trifecta. Continuation vehicles in healthcare are becoming a feature, not an anomaly — GPs are holding onto pharma platform companies longer and bringing in fresh capital rather than forcing exits into a market that may not be pricing specialty pharma correctly.

Venture Capital: Big Rounds Are Getting Bigger

The 33 VC deals this week totaled $876 million in disclosed funding. That is not the eye-popping number. The eye-popping number is $69 million — the size of Excalipoint Therapeutics' seed round. A seed round. In biotech, the definition of "early stage" is being rewritten in real time.

R1 Therapeutics raised $77.5 million in its Series A, and Crossbow Therapeutics closed $77 million in Series B — two rounds that would have been considered growth-stage just two years ago now happening at the earliest institutional stages. Midi Health's $100 million Series D pushed it past a $1 billion valuation, while Honest Health pulled in $140 million to scale value-based care for health systems.

The average seed round in healthcare this week was $18 million. The average Series A was $49 million. These are not numbers that suggest caution. They suggest a market where biotech investors believe the risk-reward profile has shifted — driven partly by AI-enabled drug discovery shortening development timelines and partly by a backlog of uncapitalized science coming out of academic labs post-pandemic.

Therapeutics Dominates, but AI Is the Through-Line

Twelve of the 47 deals were in therapeutics and oncology — the sector's traditional center of gravity. But the second-largest category, with 10 deals, was digital health and AI-enabled healthcare. This is not a coincidence. The two categories are increasingly intertwined.

WAIV, a spinout from OWKIN, raised $30 million to industrialize AI-powered oncology testing. Parallel pulled in $20 million for AI solutions in hospital administration. Health Universe raised $6 million to integrate AI agents into healthcare organizations. Even in Italy, CiaoDott raised €1.5 million pre-seed to bring vertical voice AI to the medical sector.

The pattern is consistent: AI is not a separate healthcare category anymore. It is an enabling layer that appears across therapeutics (drug discovery), diagnostics (pathology, imaging), and operations (billing, scheduling, clinical trials). Zurich-based Rivia's €13 million round to power complex clinical trials with AI and Spotlight Pathology's funding for AI cancer diagnostics both illustrate this convergence.

Europe Is Punching Above Its Weight

At least 16 of the 47 healthcare deals this week involved European companies. That is over a third, which would have been unthinkable even two years ago in a sector historically dominated by US-based biotechs.

Biorce closed a $52.5 million Series A to accelerate international expansion. Germany's Kupando raised €10 million for cancer therapeutics inspired by animal immunity — the kind of deep-science bet that European VCs are increasingly willing to make. In France, LIFEAZ raised €13 million for its "medical device as a service" model, and Kainova closed $32 million to advance cancer and inflammation therapies.

The UK also contributed, with Conduit Health's $17 million Series A and Albion Venture Capital Trusts closing a £90 million top-up offer driven by demand for UK innovation and healthcare exposure.

What to Watch in Q2

Three signals from this week's data are worth tracking through the second quarter.

First, the convergence of asset classes on healthcare is not temporary. When private credit, continuation vehicles, and strategic M&A are all active alongside VC, it means the sector's capital structure is maturing. Expect more creative deal structures — hybrid debt-equity packages, royalty financing, and structured secondaries — in healthcare through 2026.

Second, seed and Series A rounds in biotech are now sized for speed. The $69 million seed and $78 million Series A are not outliers; they reflect a market where investors want companies to reach clinical milestones faster, with fewer intermediate rounds. This compresses the timeline from founding to Phase I data, which changes everything about how biotechs are valued.

Third, European healthcare is no longer a niche allocation. One in three deals coming from Europe in a week where US mega-deals dominated the headlines suggests a structural shift in where institutional capital is finding opportunities. The gap between European biotech quality and European biotech valuations remains wide — and capital is noticing.

Forty-seven deals, $5.6 billion, five asset classes, one week. Healthcare is not just a sector right now. It is the sector where every strategy — growth, value, credit, exits — is working at the same time.